Literature DB >> 3896784

Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity.

C C Shone, P Hambleton, J Melling.   

Abstract

Limited treatment of Clostridium botulinum type A neurotoxin with trypsin resulted in the cleavage of the heavy (95000 Da) subunit at approximately the mid-position and a loss of toxic activity. The rate of toxicity loss was considerably faster than that of mid-chain cleavage; thus a loss of toxicity in excess of 90% was accompanied by only 30-35% mid-chain cleavage of the heavy subunit. A study of the binding of 125I-labelled neurotoxin to rat brain synaptosomes showed the loss of toxicity on trypsin treatment to be paralleled by a loss of toxin binding to rat brain synaptosomes suggesting the presence of at least two sites of tryptic action on the 95000-Da binding subunit. Prolonged treatment of the neurotoxin with trypsin resulted in the complete digestion of a 46000-Da fragment of the heavy subunit, leaving intact a soluble fragment of approximately 105000 Da containing the light subunit linked to the remaining (49000-Da) portion of the heavy subunit. This fragment exhibited less than 0.01% of the original toxicity and gave immunoprecipitation reactions indistinguishable from the native toxin. The 49000-Da portion of the heavy chain was purified from the 105000-Da fragment of the toxin and the sequence of the first 35 amino acids determined. The sequence of the first 10 residues was found to be identical to that previously reported for the heavy subunit showing that the 49000-Da fragment represents the NH2-terminal portion of the heavy chain and that this region is resistant to tryptic action. It is suggested that the primary site(s) of tryptic action on the heavy subunit of botulinum type A neurotoxin is close to the COOH terminus and that cleavage of the polypeptide chain in this region results in a loss of toxic activity mediated by the destruction of the neurotoxin-binding site.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896784     DOI: 10.1111/j.1432-1033.1985.tb09070.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  31 in total

Review 1.  Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use.

Authors:  P Hambleton
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

2.  Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes.

Authors:  S Kozaki; A Miki; Y Kamata; J Ogasawara; G Sakaguchi
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

3.  Inhibiting oral intoxication of botulinum neurotoxin A complex by carbohydrate receptor mimics.

Authors:  Kwangkook Lee; Kwok-Ho Lam; Anna-Magdalena Kruel; Stefan Mahrhold; Kay Perry; Luisa W Cheng; Andreas Rummel; Rongsheng Jin
Journal:  Toxicon       Date:  2015-08-10       Impact factor: 3.033

4.  Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics.

Authors:  K A Foster; E J Adams; L Durose; C J Cruttwell; E Marks; C C Shone; J A Chaddock; C L Cox; C Heaton; J M Sutton; J Wayne; F C G Alexander; D F Rogers
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

5.  Clostridium botulinum types A, B, C1, and E produce proteins with or without hemagglutinating activity: do they share common amino acid sequences and genes?

Authors:  E Somers; B R DasGupta
Journal:  J Protein Chem       Date:  1991-08

6.  Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.

Authors:  Clifford Shone; Heidi Agostini; Joanna Clancy; Mili Gu; Huei-Hsiung Yang; Yanfang Chu; Virginia Johnson; Makie Taal; Joanna McGlashan; John Brehm; Xiaomi Tong
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

Review 7.  Toxigenic clostridia.

Authors:  C L Hatheway
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

8.  The use of monoclonal antibodies to analyze the structure of Clostridium botulinum type E derivative toxin.

Authors:  S Kozaki; Y Kamata; T Nagai; J Ogasawara; G Sakaguchi
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

Review 9.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

10.  Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species.

Authors:  F Chen; G M Kuziemko; R C Stevens
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.